THERACRYF PLC Logo

THERACRYF PLC

TCF | IL

Overview

Corporate Details

ISIN(s):
GB00BMVN2C70 (+2 more)
LEI:
213800NO3E6TSTQO8K20
Country:
United Kingdom
Address:
SUITE 24G13 - BLOCK 24, SK10 4TG NETHER ALDERLEY
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

TheraCryf PLC is a clinical-stage therapeutics company developing a new generation of innovative medicines focused on oncology and behavioural brain disorders. The company's pipeline is based on sulforaphane-based therapeutics. TheraCryf's strategy is to advance its drug candidates through clinical trials to generate compelling data, with the objective of partnering its programs with mid-size to large pharmaceutical companies for late-stage development and commercialization.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for THERACRYF PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-04 16:27
Major Shareholding Notification
Holding(s) in Company
English 23.3 KB
2025-07-17 08:00
Regulatory News Service
Manufacturing Scale Up of Lead Ox-1 Programme
English 14.1 KB
2025-07-09 16:07
Post-Annual General Meeting Information
Result of AGM
English 12.3 KB
2025-06-16 17:10
Report Publication Announcement
Notice of AGM
English 13.0 KB
2025-06-10 13:32
Investor Presentation
Ox-1 Investor Presentation
English 11.6 KB
2025-06-03 08:00
Earnings Release
Final results for year to 31 March 2025
English 235.9 KB
2025-05-23 08:14
Report Publication Announcement
Notice of Results and Ox-1 presentation
English 12.5 KB
2025-05-22 13:43
Major Shareholding Notification
Holding(s) in Company
English 52.1 KB
2025-05-16 14:00
Major Shareholding Notification
Holding(s) in Company
English 23.2 KB
2025-03-26 08:00
Investor Presentation
Investor webinar
English 16.2 KB
2025-03-19 13:10
Major Shareholding Notification
Holding(s) in Company
English 23.3 KB
2025-03-17 15:17
Major Shareholding Notification
Holding(s) in Company
English 52.1 KB
2025-03-17 08:00
Major Shareholding Notification
Holding(s) in Company
English 52.3 KB
2025-03-13 08:00
Major Shareholding Notification
Holding(s) in Company
English 24.0 KB
2025-03-12 15:03
Major Shareholding Notification
Holding(s) in Company
English 23.7 KB

Automate Your Workflow. Get a real-time feed of all THERACRYF PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for THERACRYF PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN